Shinji Okabayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinji Okabayashi has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Taku Kobayashi
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
4 shared publications - Abel Botelho Quaresma
Health Sciences Postgraduate Program, IBD outpatient clinics, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil; Universidade do Oeste de Santa Catarina, UNOESC, Joaçaba, Brazil
2 shared publications - Eduard Brunet-Mas
Gastroenterlogy Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Catalunya, Spain
2 shared publications - Gilaad G. Kaplan
Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada
2 shared publications - Joseph W. Windsor
University of Calgary
2 shared publications - Lindsay Hracs
Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in SSRN Electronic Journal
Forecasting the Epidemiology of Inflammatory Bowel Disease in Brazil: A Temporal Evolution from 2012 to 2035
Background & Aims: Brazil is undergoing a rapid epidemiologic transition in inflammatory bowel disease (IBD). We aimed to characterize the temporal evolution of IBD in Brazil from 2012 to 2025 and forecast its burden through 2035, positioning the country within a global four-stage model.Methods: This nationwide, population-based study utilized the DATASUS database via the TT Disease Explorer platform. We identified individuals with Crohn’s Disease (CD), Ulcerative Colitis (UC), and IBD-Unclassifiable (IBD-U) using validated ICD-10 codes from the public healthcare system. Temporal trends (Annual Average Percent Changes: AAPCs) and autoregressive integrated moving average (ARIMA) modeling was used to forecast incidence and prevalence.Results: A total of 337,539 IBD patients were identified. Between 2012 and 2025, IBD prevalence rose from 29·85 to 158·18 per 100,000 inhabitants and IBD incidence rose from 9·35 to 12·34 per 100,000 inhabitants. The UC:CD prevalence ratio increased from 1·53:1 to 2·1:1. Hotspots were concentrated in the South and Southeast regions. ARIMA models forecast that IBD prevalence will reach 264·4 per 100,000, while incidence is forecasted to rise to 22·72 per 100,000 by 2035.Conclusions: The incidence and prevalence in Brazil are rising significantly. By 2035, this escalating burden will necessitate a structural shift in the public healthcare systems toward longitudinal models of chronic care management.
- 15 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessForecasting the Epidemiology of Inflammatory Bowel Disease in Brazil: A Temporal Evolution from 2012 to 2035
Background & Aims: Brazil is undergoing a rapid epidemiologic transition in inflammatory bowel disease (IBD). We aimed to characterize the temporal evolution of IBD in Brazil from 2012 to 2025 and forecast its burden through 2035, positioning the country within a global four-stage model.Methods: This nationwide, population-based study utilized the DATASUS database via the TT Disease Explorer platform. We identified individuals with Crohn’s Disease (CD), Ulcerative Colitis (UC), and IBD-Unclassifiable (IBD-U) using validated ICD-10 codes from the public healthcare system. Temporal trends (Annual Average Percent Changes: AAPCs) and autoregressive integrated moving average (ARIMA) modeling was used to forecast incidence and prevalence.Results: A total of 337,539 IBD patients were identified. Between 2012 and 2025, IBD prevalence rose from 29·85 to 158·18 per 100,000 inhabitants and IBD incidence rose from 9·35 to 12·34 per 100,000 inhabitants. The UC:CD prevalence ratio increased from 1·53:1 to 2·1:1. Hotspots were concentrated in the South and Southeast regions. ARIMA models forecast that IBD prevalence will reach 264·4 per 100,000, while incidence is forecasted to rise to 22·72 per 100,000 by 2035.Conclusions: The incidence and prevalence in Brazil are rising significantly. By 2035, this escalating burden will necessitate a structural shift in the public healthcare systems toward longitudinal models of chronic care management.
- 3 September 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study
Background & Aims: Acute severe ulcerative colitis (ASUC) refractory to intravenous corticosteroids (IVCS) is a major clinical challenge with limited rescue therapy options. Although tacrolimus has been proposed as a potential rescue therapy, its effectiveness and safety compared with infliximab, widely used in this setting, remain unclear. Methods: A multicenter retrospective cohort study was conducted across 34 Japanese institutions, including hospitalized patients with IVCS-refractory ASUC who received infliximab or tacrolimus as rescue therapy between January 2014 and March 2023. The primary outcome was clinical remission at day 14, using two-item patient-reported outcome scoring. Secondary outcomes included clinical response at day 3 and 7, colectomy, and adverse events within 56 days. A modified Poisson regression model was used for analysis. Results: Among 300 patients (infliximab, n = 113; tacrolimus, n = 187), clinical remission at day 14 occurred in 41.6% and 33.7%, respectively, with no difference (adjusted risk ratio [RR] 0.87 [95% CI: 0.65, 1.17]). Clinical response at day 3 was lower with tacrolimus (infliximab 42.5% vs tacrolimus 24.1%; adjusted RR 0.58 [95% CI: 0.42, 0.80]) but did not differ at day 7 (infliximab 63.7% vs tacrolimus 51.9%; adjusted RR 0.83 [95% CI: 0.69, 1.01]). No difference in colectomy within 56 days was observed, although rates were higher in the tacrolimus (13.3% vs 20.3%; adjusted RR 1.58 [95% CI: 0.93, 2.67]). Adverse events were similar between groups (infliximab 8.8% vs tacrolimus 7.5%; adjusted RR 0.77 [95% CI: 0.37, 1.57]). Conclusions: Tacrolimus demonstrated comparable effectiveness and safety to infliximab as rescue therapy for IVCS-refractory ASUC, although early response was slower.
- 3 September 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study
Background & Aims: Acute severe ulcerative colitis (ASUC) refractory to intravenous corticosteroids (IVCS) is a major clinical challenge with limited rescue therapy options. Although tacrolimus has been proposed as a potential rescue therapy, its effectiveness and safety compared with infliximab, widely used in this setting, remain unclear. Methods: A multicenter retrospective cohort study was conducted across 34 Japanese institutions, including hospitalized patients with IVCS-refractory ASUC who received infliximab or tacrolimus as rescue therapy between January 2014 and March 2023. The primary outcome was clinical remission at day 14, using two-item patient-reported outcome scoring. Secondary outcomes included clinical response at day 3 and 7, colectomy, and adverse events within 56 days. A modified Poisson regression model was used for analysis. Results: Among 300 patients (infliximab, n = 113; tacrolimus, n = 187), clinical remission at day 14 occurred in 41.6% and 33.7%, respectively, with no difference (adjusted risk ratio [RR] 0.87 [95% CI: 0.65, 1.17]). Clinical response at day 3 was lower with tacrolimus (infliximab 42.5% vs tacrolimus 24.1%; adjusted RR 0.58 [95% CI: 0.42, 0.80]) but did not differ at day 7 (infliximab 63.7% vs tacrolimus 51.9%; adjusted RR 0.83 [95% CI: 0.69, 1.01]). No difference in colectomy within 56 days was observed, although rates were higher in the tacrolimus (13.3% vs 20.3%; adjusted RR 1.58 [95% CI: 0.93, 2.67]). Adverse events were similar between groups (infliximab 8.8% vs tacrolimus 7.5%; adjusted RR 0.77 [95% CI: 0.37, 1.57]). Conclusions: Tacrolimus demonstrated comparable effectiveness and safety to infliximab as rescue therapy for IVCS-refractory ASUC, although early response was slower.
- Top Cited PapersOpen Access
- 30 April 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 458-466
Global evolution of inflammatory bowel disease across epidemiologic stages
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.
- 30 April 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 458-466
Top Cited PapersOpen AccessGlobal evolution of inflammatory bowel disease across epidemiologic stages
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.
- 26 April 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (10) , 1352-1353
Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed? Authorsʼ reply
- 26 April 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (10) , 1352-1353
Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed? Authorsʼ reply
- Open Access
- 30 April 2019
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (2) , 218-226
Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis. Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day). The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group. Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.
- 30 April 2019
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (2) , 218-226
Open AccessIndividualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis. Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day). The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group. Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.